SenesTech Announces Record Fourth Quarter and Full Year 2024 Financial Results with 70% Quarterly Revenue Growth; Gross Profit Margins of 61%; Reduction in Operating Expenses; and Dramatic Improvement in Adjusted EBITDA

Core Viewpoint - SenesTech, Inc. has reported significant financial improvements in Q4 2024, including a 70% increase in revenue and a strategic focus on operating optimization initiatives aimed at reducing expenses by approximately $2 million annually to accelerate profitability [1][7][6]. Financial Performance - Revenue for Q4 2024 increased by 70$501,000 compared to $295,000 in Q4 2023, driven by a 206$1.3 million, an improvement from a net loss of $1.7 million in Q4 2023 [5]. - Adjusted EBITDA loss for Q4 2024 was$1.1 million, down from $1.6 million in Q4 2023 [5]. Key Growth Initiatives - The Evolve™ Rat product line became the largest revenue contributor, accounting for approximately 52$2 million annually, lowering the revenue threshold for cash flow breakeven to approximately $7 million from a previous estimate of$12 million [6][8]. - The company aims to enhance operational efficiencies and streamline costs to accelerate its path to profitability [6][8]. Management Commentary - The CEO highlighted the transformational year for SenesTech, emphasizing strong financial results and the smallest quarterly Adjusted EBITDA loss in the company's history [7]. - The management is committed to a focused strategy that targets sustainable long-term success in the multi-billion-dollar rodent control market [8].